Gurmeet Singh, MD
Cardiovascular Disease · Dover, DENPI 1417927732
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 522 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations.
Across 522 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Pfizer$1K
- Johnson & Johnson$786
- Medtronic$607
- AstraZeneca$579
- E.r. Squibb & Sons, L.L.C.$569
- plus $4K from 32 others
What the payments were for
- Travel & lodging$1552%
- Food & beverage$8,83296%
- Education$2212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 87 | $1,299 |
| Pfizer | 72 | $1,037 |
| Johnson & Johnson | 49 | $786 |
| Medtronic(2 entities) | 11 | $607 |
| AstraZeneca | 33 | $579 |
| E.r. Squibb & Sons, L.L.C. | 40 | $569 |
| Amgen | 35 | $561 |
| Boehringer Ingelheim | 28 | $532 |
| Merck | 25 | $416 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $380 |
| Esperion Therapeutics, Inc. | 29 | $350 |
| Abiomed | 8 | $347 |
| Novo Nordisk | 15 | $277 |
| Bayer | 15 | $270 |
| Akcea Therapeutics, Inc. | 4 | $202 |
| Abbott | 10 | $174 |
| Boston Scientific | 2 | $156 |
| Amarin Pharma, Inc. | 6 | $85 |
| Canon Medical Systems USA, Inc. | 1 | $52 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Cook Medical LLC | 1 | $45 |
| Agepha Pharma FZ LLC | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Edwards Lifesciences | 2 | $40 |
| Heartflow, Inc. | 2 | $36 |
| Kestra Medical Technology Services, Inc. | 2 | $34 |
| Bridgebio Pharma, Inc. | 2 | $30 |
| Bardy Diagnostics, Inc. | 2 | $26 |
| Siemens Medical Solutions USA, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Sanofi | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $18 |
| Biotronik Inc. | 1 | $18 |
| Cardiva Medical, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Covidien LP | 1 | $14 |
| Daxor Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,208 in reported general payments places this provider in the 75th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 527 | $598,997 |
| XareltoRivaroxaban | 191 | $227,751 |
| EntrestoSacubitril/Valsartan | 127 | $159,636 |
| MultaqDronedarone Hcl | 43 | $73,751 |
| Repatha SureclickEvolocumab | 70 | $73,337 |
| BrilintaTicagrelor | 76 | $72,320 |
| VascepaIcosapent Ethyl | 101 | $68,798 |
| JardianceEmpagliflozin | 37 | $53,157 |
| Rosuvastatin Calcium | 1,335 | $33,237 |
| Ranolazine ErRanolazine | 199 | $22,802 |
| Ezetimibe | 477 | $20,207 |
| FarxigaDapagliflozin Propanediol | 16 | $14,780 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $13,055 |
| OzempicSemaglutide | 14 | $12,799 |
| Metoprolol Succinate | 735 | $11,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,037 | $598,997527 claims |
| Johnson & JohnsonXarelto | $786 | $227,751191 claims |
| NovartisEntresto | $1,299 | $159,636127 claims |
| AstraZenecaBrilinta, Farxiga | $579 | $87,10092 claims |
| Boehringer IngelheimJardiance | $532 | $53,15737 claims |
| Esperion Therapeutics, Inc.Nexlizet | $350 | $13,05515 claims |
| Novo NordiskOzempic | $277 | $12,79914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Dover
- Eranga HaththotuwaDover$15K
- Michael SheaDover$6K
- John ShuckDover$3K
- Khaled EljazzarDover$3K
- Jennifer EakinDover$2K
- Vinay HosmaneWilmington$256K
- Wasif QureshiBear$122K
- Rajinder PrasadLewes$72K
- Ehtasham QureshiLewes$52K
- Edward GoldenbergNewark$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.